

Hester Pharmaceuticals Limited

Regd. Off. : Village : Merda-Adraj, Ta : Kadi , Dist : Mehsana, Gujarat - 382 721

Unaudited Financial Results for the quarter ended on 30th September, 2007

Rs.in Lacs

Sr.No.	Particulars	Quarter ended on 30/09/2007 Unaudited	Quarter ended on 30/09/2006 Unaudited	Six Months ended on 30/09/2007 Unaudited	Six Months ended on 30/09/2006 Unaudited	Year ended on 31/03/2007 Audited
1	Manufacturing Sales	863.18	542.1	1712.94	1034.89	2160.11
	Trading Sales	11.85	15.09	20.26	20.56	22.68
	Net Income from Sales	875.03	557.19	1733.20	1055.45	2182.79
2	Other Income	3.94	5.59	14.55	5.67	26.32
3	Total Income	878.97	562.78	1747.75	1061.12	2209.11
4	Total Expenses	495.78	333.36	967.45	640.60	1345.73
	(a) (Increase)/decrease in Stock in trade	-44.83	-23.51	-31.67	-48.01	-225.42
	(b) Trading Purchase	19.06	0.74	38.74	10.28	30.46
	(c) Consumption of Raw material	175.88	160.25	285.67	152.59	709.37
	(d) Manufacturing Expenses	88.04	54.53	169.55	239.92	222.10
	(e) Staff Cost	65.24	44.23	121.88	86.08	196.40
	(f) Depreciation.	92.27	9.41	173.80	18.63	44.09
	(g) Selling, General & Admn. Expenses	100.12	87.71	209.48	181.11	368.73
5	Interest	70.40	14.81	141.36	24.51	69.77
6	Profit Before Tax	312.79	214.61	638.94	396.01	793.61
7	Provision for taxation	108.00	77.53	210.80	138.30	278.48
8	Net Profit	204.79	137.08	428.14	257.71	515.13
9	Paid-up equity share capital (Rs.10/- each)	519.12	519.12	519.12	519.12	519.12
10	Reserves & Surplus	-	-	-	-	2397.05
11	EPS (Rs.) (not annualised)	3.94	3.11	8.25	6.35	11.14
12	Aggregate of Non Promoters					
	- Number of Share	2952124	2971424	2952124	2971424	2969424
	- % of Shareholding	56.87	57.24	56.87	57.24	57.20

- Note:** 1. The Board of Directors have approved the aforesaid working result at their meeting held on 18th September, 2007, after reviewed by the Audit Committee of the Company
2. The Limited Review Report for the quarter as required under clause 41 of the listing agreement with Stock Exchange has been carried out by the Statutory Auditor
3. Segment wise reporting as defined in Accounting Standard (AS-17) is not applicable, since the entire operation of the Company relates to only one segment i.e. "Poultry Vaccines".
4. No investor complaints were pending at the beginning and at the end of the quarter. During the quarter, six complaints were received and resolved
5. Provision for taxation includes Current Tax, FBT and Deferred Tax Liability for the quarter as per Accounting Standard (AS-22)

By order of the Board

Place: **Ahmedabad**
Date : **18.10.2007**

Rajiv Gandhi
CEO & Managing Director